RNTX Rein Therapeutics Inc.

Price (delayed)

$1.91

Market cap

$42.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.51

Enterprise value

$29.14M

Highlights
The debt has dropped by 100% year-on-year
Rein Therapeutics's net income has plunged by 115% from the previous quarter
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ

Key stats

What are the main financial stats of RNTX
Market
Shares outstanding
21.99M
Market cap
$42.01M
Enterprise value
$29.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
EBIT
-$64.43M
EBITDA
-$64.36M
Free cash flow
-$22.29M
Per share
EPS
-$3.51
EPS diluted
-$3.51
Free cash flow per share
-$1.24
Book value per share
$2.51
Revenue per share
$0
TBVPS
$0.76
Balance sheet
Total assets
$62.19M
Total liabilities
$7.8M
Debt
$0
Equity
$54.39M
Working capital
$7.91M
Liquidity
Debt to equity
0
Current ratio
2.38
Quick ratio
2.24
Net debt/EBITDA
0.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-67.1%
Return on equity
-73.6%
Return on invested capital
N/A
Return on capital employed
-114.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNTX stock price

How has the Rein Therapeutics stock price performed over time
Intraday
4.37%
1 week
12.35%
1 month
14.37%
1 year
-61.8%
YTD
-16.96%
QTD
7.91%

Financial performance

How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 120% since the previous quarter
Rein Therapeutics's net income has plunged by 115% from the previous quarter

Growth

What is Rein Therapeutics's growth rate over time

Valuation

What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 11% since the previous quarter and by 2.6% year-on-year
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
RNTX's P/B is 42% below its 5-year quarterly average of 1.3 but 9% above its last 4 quarters average of 0.7

Efficiency

How efficient is Rein Therapeutics business performance
The ROE has plunged by 143% from the previous quarter and by 60% YoY
The ROA has plunged by 141% from the previous quarter and by 60% YoY

Dividends

What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNTX.

Financial health

How did Rein Therapeutics financials performed over time
RNTX's quick ratio is down by 43% YoY and by 28% QoQ
RNTX's current ratio is down by 43% year-on-year and by 28% since the previous quarter
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.